Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVR105 (Posoleucel) for prevention of viral infections after allogeneic hematopoietic cell transplant
2021-005105-27Phase 2Terminated
- Sponsor
- AlloVir, Inc.
- Start
- Dec 2021
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in adenoviral infection, BK polyomavirus infection, cytomegalovirus disease (CMV) and 3 more comparing Posoleucel with Placebo (2 arms). Primary endpoint: Number of clinically significant viral infections or end-organ disease episodes through Week 14. Started Dec 2021; status: terminated.
02
Drugs
posoleucel
03
Conditions
adenoviral infectionBK polyomavirus infectioncytomegalovirus disease (CMV)Epstein-Barr virus infectionhuman herpesvirus 6 infection
Beyond the preview
Go deeper on 2021-005105-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005105-27.